Università degli Studi di Perugia
Perugia, PG, 06100, Italy
Location status: Recruiting
NCT Number: NCT06845592
The study is a monocentric, interventional study that evaluates the efficacy of allogeneic HLA-matched or haploidentical transplantation consisting of an irradiation-based conditioning regimen coupled with donor Treg/Tcon adoptive immunotherapy for high-risk acute leukemia patients.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Perugia, PG, 06100, Italy
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
ALL patients
Exclusion criteria
Combination of 20 Gy TMLI with Treg/Tcon adoptive immunotherapy in allogeneic cell transplantation
Time frame: 2 years
The primary objective of the study is to reduce the incidence of disease relapse after irradiation-based conditioning regimen and Treg/Tcon adoptive immunotherapy-based allogeneic transplantation from HLA-matched or haploidentical donors in high-risk acute leukemia patients.
Time frame: 45 days
The study will also evaluate the impact of the allogeneic transplantation from HLA-matched or haploidentical donors with irradiation-based conditioning regimen and Treg/Tcon adoptive immunotherapy on major transplantation outcomes in high-risk acute leukemia patients such as full donor type engraftment.
Time frame: 2 years
The study will also evaluate the impact of the allogeneic transplantation from HLA-matched or haploidentical donors with irradiation-based conditioning regimen and Treg/Tcon adoptive immunotherapy on major transplantation outcomes in high-risk acute leukemia patients such as grade ≥ 2 acute GvHD.
Time frame: 2 years
The study will also evaluate the impact of the allogeneic transplantation from HLA-matched or haploidentical donors with irradiation-based conditioning regimen and Treg/Tcon adoptive immunotherapy on major transplantation outcomes in high-risk acute leukemia patients such as chronic GvHD.
Contact information is provided by the study sponsor or research team.
University Of Perugia
Other
SHARP - Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia
Acronym: SHARP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06987058
Acute Myeloid Leukaemia (AML), Advanced Solid Tumors
Gdansk, Poland
View Trial DetailsNCT07154823
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Iowa City, Iowa, United States
View Trial DetailsNCT06788756
Acute Myeloid Leukaemia (AML), Hematologic Diseases
Miami, Florida, United States
View Trial DetailsNCT07148180
Acute Myeloid Leukaemia (AML), Blood Cancer
Boston, Massachusetts, United States
View Trial Details